Is Amicus Therapeutics, Inc. (0HF9.L) a Buy, Sell, or Hold?
LSE : 0HF9.L
Amicus Therapeutics, Inc.
$17.09 USD
$2.63 (18.19%)
- Volume
- 366
- Average Volume
- 814
- Market Capitalization
- $5.27B
- P/E Ratio
- -163.73
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $17.09
- Year Low
- $9.74
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.84
Company Overview
LSE
Bradley L. Campbell
Medical - Pharmaceuticals
Healthcare
0HF9.L
499
US
USD
Liquidity Metrics
1.76
2.84
1.88
0.90
0.00
Sales & Valuation
$634.21M
7.17
16.33
152.43
0.10
Profitability
-$0.0879
-$27.11M
-4.27%
0.03%
-12.02%
-2.85%
P/E Metrics
-163.73
1.68
1.68
Analyst Price Target & Rating
0/5
24 Analysts
%
Financial Health Scores
1.98
3/9
$438.34M
$949.87M
$675.63M
$46.21M
Key Metrics (TTM)
No key metrics data available.
Company Executives
| Name | Title |
|---|---|
| Bradley L. Campbell | Chief Executive Officer, President & Director |
| Andrew Faughnan | Vice President of Investor Relations |
| Jeffrey Castelli | Chief Development Officer |
| Jill Weimer | Chief Science Officer |
| Simon Nicolas Reade Harford | Chief Financial Officer |
| Ellen S. Rosenberg | Chief Legal Officer & Corporate Secretary |
| Samantha Prout | Chief Accounting Officer & Controller |
| Brendan McEvoy | Executive Director of External Communications |
| David Clark | Chief People Officer |
| Patrik S. Florencio | Global Chief Compliance & Risk Officer |
Poll Results
No votes yet today — be the first to share your view!
About Amicus Therapeutics, Inc. (LSE:0HF9.L) Stock
Amicus Therapeutics, a biotechnology enterprise, is committed to the research, development, and commercialization of therapeutic solutions for rare genetic conditions. Its flagship commercial product, Galafold, is a precise, orally administered medication intended for adult patients with a verified diagnosis of Fabry disease who possess a treatable galactosidase alpha gene variant, as indicated by in vitro laboratory assays. The company's robust development pipeline features AT-GAA, an innovative therapeutic approach for Pompe disease, in addition to other enzyme replacement therapies targeting this same condition. Amicus is also conducting a Phase 1/2 clinical trial for CLN3, which is assessing the safety and effectiveness of a solitary intrathecal administration of its AT-GTX-502 gene th ... erapy (an AAV serotype) in affected individuals. Furthermore, research efforts are underway for therapies related to CDKL5, an X-linked gene responsible for coding a protein crucial for regulating essential brain development proteins. Amicus Therapeutics maintains strategic collaboration and licensing agreements with prominent entities such as Nationwide Children's Hospital, the University of Pennsylvania, and GlaxoSmithKline. Established in 2002, the company's corporate headquarters are located in Philadelphia, Pennsylvania.
Frequently Asked Questions
-
What is the current Amicus Therapeutics, Inc. (0HF9.L) stock price?
-
Amicus Therapeutics, Inc.(LSE:0HF9.L) stock price is $17.09 in the last trading session. During the trading session, 0HF9.L stock reached the peak price of $17.09 while $9.7388 was the lowest point it dropped to. The percentage change in 0HF9.L stock occurred in the recent session was 18.19% while the dollar amount for the price change in 0HF9.L stock was $2.63.
-
0HF9.L's industry and sector of operation?
-
The LSE listed 0HF9.L is part of Medical - Pharmaceuticals industry that operates in the broader Healthcare sector.
-
Who are the executives of 0HF9.L?
-
Bradley L. Campbell | Chief Executive Officer, President & Director
Andrew Faughnan | Vice President of Investor Relations
Jeffrey Castelli | Chief Development Officer
Jill Weimer | Chief Science Officer
Simon Nicolas Reade Harford | Chief Financial Officer -
How many employees does 0HF9.L have?
-
Number of 0HF9.L employees currently stands at 499. 0HF9.L operates from 3675 Market Street, Philadelphia, PA 19104, US.
-
Link for 0HF9.L official website?
-
Official Website of 0HF9.L is: https://amicusrx.com
-
How do I contact 0HF9.L?
-
0HF9.L could be contacted at phone #215 921 7600 and can also be accessed through its website. 0HF9.L operates from 3675 Market Street, Philadelphia, PA 19104, US.
-
How many shares of 0HF9.L are traded daily?
-
The average number of 0HF9.L shares traded daily for last 3 months was 814.
-
What is the market cap of 0HF9.L currently?
-
The market value of 0HF9.L currently stands at $5.27B with its latest stock price at $17.09